share_log

Apollomics To Be Listed on Nasdaq Through Business Combination With Maxpro Capital Acquisition Corp.; Transaction Values Apollomics At Pre-Money Equity Value Of $899M

Apollomics To Be Listed on Nasdaq Through Business Combination With Maxpro Capital Acquisition Corp.; Transaction Values Apollomics At Pre-Money Equity Value Of $899M

Apollomics将通过与Maxpro Capital收购公司的业务合并在纳斯达克上市；交易估值Apollomics的盘前股权价值为8.99亿美元
Benzinga Real-time News ·  2022/09/14 08:34

Apollomics Inc. ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. ("Maxpro") (NASDAQ:JMAC, , JMACU, , JMACW))))) today announced a definitive agreement for a business combination (the "Transaction" or the "Business Combination") that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market ("Nasdaq"). The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol "APLM."

后期临床生物制药公司Apollomics Inc.（“Apollomics” 或 “公司”）和Maxpro Capital Acquition Corp.（“Maxpro”）（纳斯达克股票代码：JMAC、、JMACU、JMACW）））今天宣布就业务合并（“交易” 或 “业务合并”）达成最终协议，这将导致Apollomics成为上市公司在纳斯达克全球市场（“纳斯达克”）上。该业务合并预计将于2023年第一季度完成，Apollomics有望在纳斯达克上市，股票代码为 “APLM”。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发